Baktiar Karim in the Molecular Histopathology Laboratory at the Frederick National Laboratory for Cancer Research.

While advancing age is the most important risk factor for cancer, the incidence of the disease decreases in very elderly people.

 Dr. Ian Crozier (right) and colleague Dr. Ali Dilu from the Institut National pour la Rechere Biomedicale en route by helicopter to Komanda in the DRC  to deliver urgent investigational product and training to the Komanda Ebola Treatment Center in February 2019.

Dr. Ian Crozier Draws on His Own Experience to Inform Studies in Humans and in the Lab

Surviving very severe Ebola virus disease made it clear to Ian Crozier, M.D., that there was a gap to bridge between clinicians caring for patients at outbreak bedsides and the bench scientists peering into fundamental mechanisms of disease to develop prevention and treatment strategies.

Frederick National Laboratory Part of SC19 “Best Paper” Team

A multidisciplinary team including members of the Frederick National Laboratory has been recognized with the “Best Paper” award at SC19, a prestigious international conference for high-performance computing, networking, storage, and analysis. Of the 344 papers submitted to SC19, only 87 were accepted, and just one was named Best Paper.

Families go to the Ebola Treatment Center to visit a family member who is held in quarantine. [Credit: World Bank/Vincent Tremeau, republished here under CC BY-NC-ND 2.0]

FREDERICK, Md. -- “Sure, it’s easier than doing research in more isolated places, say Antarctica, or outer space—but that does not make it easy for those on the ground. Sometimes densely populated areas pose problems of their own. Not everyone agrees on the need, the presence of so many ‘outsiders,’ or on the approach taken. People were attacked. Research sites were burned.”

Molecular Cancer Therapeutics journal cover featuring the FNL study.

FREDERICK, Md. -- High levels of the enzyme tyrosine threonine kinase (TTK) in many types of cancer cells, including lung cancer, contribute to uncontrolled cell growth. A study published by Frederick National Laboratory Director Ethan Dmitrovsky, M.D. and his laboratory team demonstrated that a promising anti-TTK treatment that acts against many of those types of cancer cells also results in lung cancer cell death. 

Image of original whole-slide image of liver tumor with annotation by pathologists, courtesy PAIP 2019.

FREDERICK, Md. – Frederick National Laboratory for Cancer Research’s medical imaging expertise received the highest rating at a recent grand challenge for pathology that featured nearly 1,000 competitors from around the world.

Tanja Grkovic inspects a 384 well plate containing natural product chemical fractions before it is shipped out for screening.

FREDERICK, Md. -- Tree bark, microbes, and mold are not simply the stuff you rake in the back yard and track in on the bottom of your shoes. They just might be a treatment for a rare disease. 

Products found in nature gave rise to some of our most familiar and relied-upon therapies including some antibiotics and decongestants and aspirin. There may be another treatment contained in a sea sponge or a leaf, but sifting through to isolate that compound is a complex undertaking. Scientists find natural products notoriously difficult to work with.

Stock image of stethoscope and medical papers.

Ethan Dmitrovsky: X Factor

Published: 11/21/2019Tagged:

"While medicine, like physics, uses probability to help solve its problems, only medicine includes the human element as a factor in its calculations."

A Janus G3 Automated Workstation at the Cancer Genomics Research Laboratory, one of the instruments used to conduct the TypeSeq assay.

FREDERICK, Md. -- Scientists at the Frederick National Laboratory for Cancer Research, the National Cancer Institute, and other collaborating institutions have demonstrated that their recently developed technique for detecting human papillomavirus (HPV) in patient samples performs comparably to existing gold-standard methods.

Biophysical Journal, The Premier Journal of Quantitative Biology, Volume 116, Number 6, March 19, 2019,, Biophysical Society, Cell Press

FREDERICK, Md. -- A study defining how an oncogenic protein gets removed from its active spot may offer new ways to target unwanted cell growth, a hallmark of cancer.

KRAS is a membrane-binding protein that functions as a molecular switch to regulate cellular activity, and is the most frequently mutated oncogene in human cancer. Normal KRAS controls cell growth. When KRAS is mutated, the signal is disrupted and cells grow continuously.